×
USE OF REMDESIVIR IN KIDNEY TRANSPLANT RECIPIENTS WITH SARS-COV-2 OMICRON INFECTION.
https://doi.org/10.1016/j.kint.2022.08.001
Kidney International; Cacho J, Nicolás D et. al.

Aug 15th, 2022 - USE OF REMDESIVIR IN KIDNEY TRANSPLANT RECIPIENTS WITH SARS-COV-2 OMICRON INFECTION.|2022|Cacho J,Nicolás D,Bodro M,Cuadrado-Payán E,Torres-Jaramillo V,|

Comparative-effectiveness research of COVID-19 treatment: a rapid scoping review.
https://doi.org/10.1136/bmjopen-2020-045115
BMJ Open; Pham B, Rios P et. al.

Aug 11th, 2022 - The COVID-19 pandemic has stimulated growing research on treatment options. We aim to provide an overview of the characteristics of studies evaluating COVID-19 treatment. Rapid scoping review DATA SOURCES: Medline, Embase and biorxiv/medrxiv from inception to 15 May 2021. Hospital and community care. COVID-19 patients of all ages. COVID-19 treatment. The literature search identified 616 relevan...

Utilizing Labour and Delivery for remdesivir infusion for high-risk pregnant and postpa...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356568
The Journal of Hospital Infection; Herz-Roiphe R, Kim AY et. al.

Aug 10th, 2022 - Utilizing Labour and Delivery for remdesivir infusion for high-risk pregnant and postpartum patients with mild-to-moderate disease during a COVID-19 surge.|2022|Herz-Roiphe R,Kim AY,Kaimal AJ,Goldfarb IT,|

Selective serotonin reuptake inhibitor (SSRI) antidepressants reduce COVID-19 infection...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9360648
European Journal of Clinical Pharmacology; Foletto VS, da Rosa TF et. al.

Aug 10th, 2022 - The absence of specific treatments for COVID-19 leads to an intense global effort in the search for new therapeutic interventions and better clinical outcomes for patients. This review aimed to present a selection of accepted studies that reported the activity of antidepressant drugs belonging to the selective serotonin receptor inhibitor (SSRI) class for treating the novel coronavirus. A searc...

Paxlovid - nirmatrelvir and ritonavir kit-Pfizer Laboratories Div Pfizer Inc
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bdddfba-bd31-44cb-ba9e-23a4e17a4691

Aug 10th, 2022 - The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PAXLOVID for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV...

Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 : A Randomized C...
https://doi.org/10.7326/M22-1503
Annals of Internal Medicine;

Aug 9th, 2022 - Ensovibep (MP0420) is a designed ankyrin repeat protein, a novel class of engineered proteins, under investigation as a treatment of SARS-CoV-2 infection. To investigate if ensovibep, in addition to remdesivir and other standard care, improves clinical outcomes among patients hospitalized with COVID-19 compared with standard care alone. Double-blind, randomized, placebo-controlled, clinical tri...

COVID-19 Vaccination and Remdesivir are Associated With Protection From New or Increase...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9343962
Transplant International : Official Journal of the Europe... Killian JT, Houp JA et. al.

Aug 6th, 2022 - Alloimmune responses in kidney transplant (KT) patients previously hospitalized with COVID-19 are understudied. We analyzed a cohort of 112 kidney transplant recipients who were hospitalized following a positive SARS-CoV-2 test result during the first 20 months of the COVID-19 pandemic. We found a cumulative incidence of 17% for the development of new donor-specific antibodies (DSA) or increase...

Bebtelovimab - bebtelovimab injection, solution-Eli Lilly and Company
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd8dc07c-3aae-4cc2-a547-3a19357411ca

Aug 5th, 2022 - SPL UNCLASSIFIED SECTION HIGHLIGHTS OF EMERGENCY USE AUTHORIZATION (EUA) These highlights of the EUA do not include all the information needed to use BEBTELOVIMAB under the EUA. See the FULL FACT SHEET FOR HEALTHCARE PROVIDERS for BEBTELOVIMAB. BEBTELOVIMAB injection for intravenous use Original EUA Authorized Date: 02/2022 Revised EUA Authorized Date: 08/2022 ----------------------------RECENT...

Combination therapy with remdesivir and immunomodulators improves respiratory status in...
https://doi.org/10.1002/jmv.28037
Journal of Medical Virology; Kojima Y, Nakakubo S et. al.

Aug 3rd, 2022 - Immunomodulators (tocilizumab/baricitinib) improve outcomes of coronavirus disease 2019 (COVID-19) patients, but the synergistic effect of remdesivir is unknown. The effect of combination therapy with remdesivir, immunomodulators, and standard treatment in COVID-19 patients was investigated. This retrospective, single-center study included COVID-19 patients who were treated with tocilizumab or ...

Asia Pacific perspectives on the second year of the COVID-19 pandemic: A follow-up survey.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353384
Clinical and Experimental Allergy : Journal of the Britis... Pawankar R, Thong BY et. al.

Jul 31st, 2022 - The Coronavirus disease 2019 (COVID-19) pandemic is currently in its third year. This follow-up survey was commissioned by the Asia Pacific Association of Allergy Asthma and Clinical Immunology (APAAACI) Task Force on COVID-19 to compare and contrast changes in the epidemiology, clinical profile, therapeutics and public health measures of the pandemic in the Asia Pacific region. A questionnaire...

Current evidence on the use of anakinra in COVID-19.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296834
International Immunopharmacology; Khani E, Shahrabi M et. al.

Jul 30th, 2022 - Despite the progressing knowledge in COVID-19 management, remdesivir is the only agent that got approval to inhibit viral replication. However, there are limited data about effective immunomodulatory agents to prevent cytokine release in COVID-19. Cytokine release syndrome in COVID-19 resembles secondary hemophagocytic lymphohistiocytosis, in which interleukin-1 (IL-1) plays a key role. Anakinr...

Clinically Relevant Interactions Between Ritonavir-Boosted Nirmatrelvir and Concomitant...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325946
Clinical Pharmacokinetics; Wanounou M, Caraco Y et. al.

Jul 28th, 2022 - Ritonavir-boosted nirmatrelvir (RBN) has been authorized recently in several countries as an orally active anti-SARS-CoV-2 treatment for patients at high risk of progressing to severe COVID-19 disease. Nirmatrelvir is the active component against the SARS-CoV-2 virus, whereas ritonavir, a potent CYP3A inhibitor, is intended to boost the activity of nirmatrelvir by increasing its concentration i...

Remdesivir (VEKLURY) for treating COVID-19: Guinea pig ex vivo and in vivo cardiac elec...
https://doi.org/10.1097/FJC.0000000000001321
Journal of Cardiovascular Pharmacology; Pilote S, Simard C et. al.

Jul 27th, 2022 - Bradycardia and QTc interval prolongation on the ECG have been reported with remdesivir (Veklury®), an antiviral drug recently approved for treating severely ill COVID-19 patients. The objective was to evaluate the effects of remdesivir on cardiac electrophysiology ex vivo and in vivo. Ex vivo: Langendorff retroperfusion experiments were performed on isolated hearts from male Hartley guinea pig...

Antivirals May Reduce Hospitalizations and Deaths in COVID
https://www.medscape.com/viewarticle/977948

Jul 26th, 2022 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Patients with nonsevere COVID-19 may avoid progression to hospitalization or death through treatment with nirmatrelvir-ritonavir or molnupiravir, according to a systematic review and meta-analysis. In trials conducted mostly in unvaccinated patients who had been infected with the Delta variant, ...

Antiviral drug treatment for nonsevere COVID-19: a systematic review and network meta-a...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328465
CMAJ : Canadian Medical Association Journal = Journal De ... Pitre T, Van Alstine R et. al.

Jul 26th, 2022 - Randomized trial evidence suggests that some antiviral drugs are effective in patients with COVID-19. However, the comparative effectiveness of antiviral drugs in nonsevere COVID-19 is unclear. We searched the Epistemonikos COVID-19 L·OVE (Living Overview of Evidence) database for randomized trials comparing antiviral treatments, standard care or placebo in adult patients with nonsevere COVID-1...

Drug-drug interaction between remdesivir and immunosuppressant agents in a kidney trans...
https://doi.org/10.5414/CP204239
International Journal of Clinical Pharmacology and Therap... Hirai T, Mizuta A et. al.

Jul 22nd, 2022 - A 60-year-old man was treated with a regimen of controlled-release tacrolimus (2 mg once daily), everolimus (0.5 mg twice daily), methylprednisolone (4 mg once daily), and mizoribine (100 mg twice daily) as an anti-rejection regimen following living-donor kidney transplantation. One year after transplantation, the recipient was admitted to Mie University Hospital (day X; admission date) to trea...

Trends in COVID-19 patient characteristics in a large electronic health record database...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299343
PloS One; Liang C, Ogilvie RP et. al.

Jul 21st, 2022 - Electronic health record (EHR) databases provide an opportunity to facilitate characterization and trends in patients with COVID-19. Patients with COVID-19 were identified based on an ICD-10 diagnosis code for COVID-19 (U07.1) and/or a positive SARS-CoV-2 viral lab result from January 2020 to November 2020. Patients were characterized in terms of demographics, healthcare utilization, clinical c...

High-Dose Inhaled Nitric Oxide for the Treatment of Spontaneously Breathing Pregnant Pa...
https://doi.org/10.1097/AOG.0000000000004847
Obstetrics and Gynecology; Valsecchi C, Winterton D et. al.

Jul 20th, 2022 - To evaluate whether the use of inhaled nitric oxide (iNO)200 improves respiratory function. This retrospective cohort study used data from pregnant patients hospitalized with severe bilateral coronavirus disease 2019 (COVID-19) pneumonia at four teaching hospitals between March 2020 and December 2021. Two cohorts were identified: 1) those receiving standard of care alone (SoC cohort) and 2) tho...

Stenotrophomonas maltophilia Infection Associated with COVID-19: A Case Series and Lite...
https://doi.org/10.12659/AJCR.936889
The American Journal of Case Reports; Ishikawa K, Nakamura T et. al.

Jul 20th, 2022 - BACKGROUND We aimed to identify the risk factors for Stenotrophomonas maltophilia infection in patients with COVID-19. CASE REPORT Case 1. A 52-year-old COVID-19-positive woman with systemic lupus erythematosus was administered remdesivir (RDV) and methylprednisolone (mPSL) 1000 mg/day for 3 days, and subsequently administered baricitinib and ceftriaxone. Following respiratory deterioration, sh...

Therapeutic Management of COVID-19 in a Pediatric Patient with Neurodegenerative CLN2 D...
https://doi.org/10.1055/s-0042-1750729
Neuropediatrics Schwering C, Apostolidou S et. al.

Jul 18th, 2022 - The 12 years old male patient presented here suffers from neuronal ceroid lipofuscinoses 2 (CLN2) (MIM# 204500) and receives intracerebroventricular enzyme replacement therapy (ICV-ERT) every 14 days. After the emergence of the coronavirus disease 2019 (COVID-19) pandemic, routine care of children and adolescents with rare chronic diseases has become challenging. Although, in general, children ...